PT  - JOURNAL ARTICLE
AU  - Hoyle, Brian
ED  - Bourlière, Marc
TI  - HCV—Infected Patients with Compensated Cirrhosis Benefit from 12-Week, Once-Daily, Oral Combination of LDV and SOF
DP  - 2014  01
TA  - MD Conference Express
PG  - 21--21
VI  - 14
IP  - 48
4099  - http://mdc.sagepub.com/content/14/48/21.short
4100  - http://mdc.sagepub.com/content/14/48/21.full
AB  - The once-daily, oral, 12-week regimen using a single tablet combination of sofosbuvir (SOF; 400 mg) and ledipasvir (LDV; 90 mg) with or without ribavirin produces high sustained virologic response 12 weeks after conclusion of treatment in hepatitis C virus (HCV)-infected patients with compensated cirrhosis. This article discussed a study comprised of pooled data from the LONESTAR, ELECTRON and ELECTRON-2, ION-1 and ION-2, and SIRIUS trials.